Osteopenia Management Guidelines

Introduction to Osteopenia Treatment

Patients on systemic steroid therapy should receive calcium and vitamin D supplementation for the duration of treatment, and measurement of bone density is recommended at the initiation of steroid therapy 1

Oral bisphosphonates (e.g., alendronate 70 mg once weekly or risedronate 35 mg once weekly) are recommended as first-line therapy due to safety, cost, and established efficacy, with low-quality evidence showing risedronate may reduce fracture risk by 73% compared to placebo in women with advanced osteopenia 2, 3
The American College of Physicians recommends against menopausal estrogen therapy or raloxifene for osteopenia treatment due to potential harms, although patients on aromatase inhibitors or androgen deprivation therapy may benefit from bisphosphonates or denosumab 4, 2
Zoledronic acid 5 mg IV every 2 years or denosumab 60 mg subcutaneously every 6 months may be considered for patients who cannot tolerate oral bisphosphonates or have contraindications to bisphosphonates 5
IV bisphosphonates, teriparatide, denosumab, and raloxifene may be considered in specific situations, such as when oral bisphosphonates are not appropriate or contraindicated 3

Lifestyle modifications, including regular weight-bearing and muscle-strengthening exercises, a balanced diet, and avoidance of tobacco use and excessive alcohol intake, are essential for managing osteopenia 6, 5, 7, 8
Patients with osteopenia should perform regular weight-bearing exercise (at least 30 minutes, 3 days a week) and receive calcium and vitamin D supplementation, as recommended by the Journal of Hepatology and the American College of Rheumatology (calcium intake of 1000-1200 mg daily and vitamin D intake of 600-800 IU daily) 9, 6
Maintaining a healthy lifestyle, including quitting smoking, limiting alcohol intake to 1-2 alcoholic beverages/day, and following a balanced diet, is recommended for patients with osteopenia 6, 5, 7, 8

Bone mineral density (BMD) testing should be performed every 2-3 years for patients with osteopenia, with more frequent monitoring for high-risk patients, such as those on high-dose glucocorticoids 4, 9, 3
Densitometry (DXA) is the standard method for diagnosing osteoporosis, with indications including women ≥65 years and men ≥70 years, postmenopausal women <65 years with risk factors, and adults with fragility fractures or conditions associated with low bone mass 10
Vertebral fracture assessment (VFA) is useful for identifying undiagnosed vertebral fractures, with minimal radiation exposure and low cost 10

Evaluate and treat underlying conditions that may contribute to bone loss, such as vitamin D deficiency, hyperparathyroidism, hyperthyroidism, malabsorption disorders, chronic kidney disease, and medications (e.g., glucocorticoids, anticonvulsants) 11, 8
Patients on systemic steroid therapy should receive calcium and vitamin D supplementation for the duration of treatment, and patients with inflammatory conditions should have treatment of underlying disease activity, with tight control of disease activity plus calcium/vitamin D supplementation increasing BMD by 0.76% annually 8

A comprehensive fracture risk assessment should be performed when osteopenia is identified, including calculating 10-year fracture risk using the FRAX tool and identifying additional clinical risk factors 3
Consider pharmacologic treatment when T-score is less than -1.5 with additional risk factors, 10-year risk of major osteoporotic fracture ≥20%, or 10-year risk of hip fracture ≥3% (based on FRAX tool) 11, 12, 5
Previous fragility fractures, especially vertebral fractures, increase the risk of new vertebral fractures 5-fold, according to the National Comprehensive Cancer Network and the Journal of the National Comprehensive Cancer Network 4
Age is a clinical risk factor, with increased risk associated with advancing age, and family history of hip fracture, low body weight, smoking, and excessive alcohol consumption are also risk factors 4
Patients with existing vertebral fractures have a 5-fold increased risk of new vertebral fractures and 2-fold increased risk of hip fracture 4
Annual clinical fracture risk reassessment is necessary to adjust treatment plans accordingly 4, 3

Fall prevention measures, including balance training, home hazard assessment, medication review, vision assessment, and appropriate footwear, are essential for patients with osteopenia 4, 2, 5, 13